Silence Therapeutics plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Silence Therapeutics plc (SLNCF) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $6.93 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-05
- Silence Therapeutics plc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $6.93, a 45.00% decline from fiscal 2024.
- Silence Therapeutics plc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $12.60, a 34.04% increase from fiscal 2023.
- Silence Therapeutics plc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $9.40, a 18.26% decline from fiscal 2022.
- Silence Therapeutics plc share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $11.50.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2025-12-31 | $6.93 10-K · filed 2026-03-05 |
| 2024-12-31 | $12.60 10-K · filed 2026-03-05 |
| 2023-12-31 | $9.40 10-K · filed 2025-02-27 |
| 2022-12-31 | $11.50 10-K · filed 2025-02-27 |